Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.

J Infect Dis. 2000 Apr;181(4):1264-72. Unique Identifier : AIDSLINE MED/20227748
Haslett PA; Nixon DF; Shen Z; Larsson M; Cox WI; Manandhar R; Donahoe SM; Kaplan G; Laboratory of Cellular Physiology and Immunology, Rockefeller; University, New York, NY 10021, USA.; hasletp@rockvax.rockefeller.edu

Abstract: Virus-specific CD4+ T-helper cell function is important in controlling human immunodeficiency virus (HIV) infection but is impaired in patients with progressive HIV disease. It has been reported that after highly active antiretroviral therapy (HAART), HIV-specific lymphoproliferative responses remain absent, whereas responses to non-HIV microbial antigens are restored. However, in analyzing immune responses in a cohort of chronically infected adults on HAART, we observed strong HIV-specific CD4+ T cell responses of Th-1 phenotype in 11 of 22 patients. The magnitude and frequency of HIV-specific lymphoproliferative responses was strongly associated with previous interruptions in HAART (P=.001). In contrast, the magnitude of CD8+ T cell responses to HIV Gag, Pol, Env, and Nef was similar in patients who had and those who had not interrupted HAART. We conclude that (1) a significant proportion of chronically HIV-infected patients on HAART can generate strong HIV-specific CD4+ and CD8+ T cell immunity and (2) transient interruptions in antiviral treatment may prime or boost HIV-specific CD4+ T-helper responses.

Keywords: JOURNAL ARTICLE Adult Aged Anti-HIV Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Antibodies, Viral/BIOSYNTHESIS Cell Separation Cohort Studies CD4 Lymphocyte Count Drug Administration Schedule Drug Therapy, Combination Female Flow Cytometry Gene Products, gag/BIOSYNTHESIS Human HIV/*PHYSIOLOGY HIV Infections/*DRUG THERAPY/*IMMUNOLOGY Interferon Type II/METABOLISM Male Middle Age Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes, Helper-Inducer/*PHYSIOLOGY Virus Replication

000830
A0080958

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .